Supplementary Materials

Supplementary Material for:

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

Jacalyn Rosenblatt,* Richard M. Stone, Lynne Uhl, Donna Neuberg, Robin Joyce, James D. Levine, Jon Arnason, Malgorzata McMasters, Katarina Luptakova, Salvia Jain, Jeffrey I. Zwicker, Ayad Hamdan, Vassiliki Boussiotis, David P. Steensma, Daniel J. DeAngelo, Ilene Galinsky, Poorvi Somaiya Dutt, Emma Logan, Mary Paty Bryant, Dina Stroopinsky, Lillian Werner, Kristen Palmer, Max Coll, Abigail Washington, Leandra Cole, Donald Kufe, David Avigan

*Corresponding author. Email: jrosenb1{at}bidmc.harvard.edu

Published 7 December 2016, Sci. Transl. Med. 8, 368ra171 (2016)
DOI: 10.1126/scitranslmed.aag1298

This PDF file includes:

  • Fig. S1. Expansion of leukemia-specific CD4+ and CD8+ T cells after vaccination.
  • Fig. S2. Expansion of MUC1, WT1, NY-ESO pentamer+ cells after vaccination.
  • Fig. S3. Increased presence of leukemia-reactive T cells in the bone marrow after vaccination.
  • Fig. S4. T cell phenotype before and after vaccination.
  • Table S1. Cytogenetic and molecular risk profile.
  • Table S2. Reasons for withdrawal before DC collection.
  • Table S3. Vaccine characterization.
  • Table S4. Potency of vaccine preparations as antigen-presenting cells.

[Download PDF]